Four major pharmaceutical companies involved in the first U.S. negotiations over Medicare drug prices expect limited business impact despite anticipated price cuts. Bristol Myers Squibb & Co (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), AbbVie Inc (NYSE:ABBV), and AstraZeneca Plc (NASDAQ:AZN) expressed this outlook after reviewing confidential government pricing set to take effect in 2026. Reuters noted that executives shared their perspectives during recent quarterly conference calls. Related: Medicare’s Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029. The Medicare program, covering 66 million Americans aged 65 and older or with disabilities, spends billions annually on medications. It plans to cut drug list prices by at least 25% in 2026, with official announcements